ASX:LDX Lumos Diagnostics (LDX) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free LDX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Lumos Diagnostics alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Lumos DiagnosticsLumos Diagnostics Holdings Limited, a contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. The company's products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.Read More Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details LDX Stock News HeadlinesApril 11, 2024 | proactiveinvestors.comLumos Diagnostics’ breakthroughs in paediatric care with FebriDxJanuary 30, 2024 | msn.comASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDAMay 5, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. November 11, 2023 | investing.comLumos Diagnostics Holdings Ltd (LDX)September 10, 2023 | finance.yahoo.comLumos Diagnostics Holdings Limited (LDX.AX)September 1, 2023 | finance.yahoo.comLumos Diagnostics Holdings Full Year 2023 Earnings: US$0.038 loss per share (vs US$0.30 loss in FY 2022)August 23, 2023 | wsj.comLumos Diagnostics Holdings Ltd.August 18, 2023 | finance.yahoo.comLumos Receives US FDA Clearance for FebriDx®May 5, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. February 15, 2022 | finance.yahoo.comLiverpool CCG and Community Pharmacy Liverpool Launch FebriDx® Service at More Than 100 Community PharmaciesSee More Headlines Receive LDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lumos Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolASX:LDX CUSIPN/A CIKN/A Weblumosdiagnostics.com Phone61 3 9692 7222FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,820,000.00 Net Margins-107.38% Pretax MarginN/A Return on Equity-87.62% Return on Assets-26.13% Debt Debt-to-Equity Ratio92.41 Current Ratio0.69 Quick Ratio0.77 Sales & Book Value Annual Sales$8.21 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares481,300,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.74 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Samuel LanyonExecutive ChairmanMr. Douglas WardCEO, MD & DirectorMr. Barrie LambertChief Financial OfficerDr. Sacha Dopheide Ph.D.Chief Technology OfficerMs. Jennifer ChristiansenVice President of Corporate Marketing & CommunicationsMs. Sarah GlubkaSenior Director of Human ResourcesMr. Paul KaseSenior Vice President of Commercial OperationsMs. Tracy Weimar BAMBA, Company SecretaryMore ExecutivesKey CompetitorsAmerican Bio MedicaOTCMKTS:ABMCANGLEOTCMKTS:ANPCYAustralian Clinical LabsASX:ACLBARD1 Life SciencesASX:BD1BCAL DiagnosticsASX:BDXView All CompetitorsInsidersDoug WardBought 250,000 shares on 10/18/2023Total: $21,750.00 ($0.09/share)Catherine RobsonSold 428,571 sharesTotal: $29,999.97 ($0.07/share) This page (ASX:LDX) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsCharles Payne Demystifies OptionsUnstoppable ProsperityDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Diagnostics Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
